EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
|
EQS-Ad-hoc: Eckert Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results Berlin, April 25, 2023. According to preliminary calculations, Eckert Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around 58 million EUR (previous year: 50) and a net profit of around 4.7 million EUR (previous year: 6.6) for the first quarter of 2023. The significant increase in sales results from the renewed growth in demand for radioisotopes for pharmaceutical and industrial applications. This is offset by a lower gross margin due to a weaker product mix in the Isotope Products segment. The main drivers of the decline in earnings compared to the previous year are however losses in the context of valuations of balance sheet items in foreign currencies and inflation adjustments in the hyperinflationary country of Argentina, which were not included in the first quarter of the previous year, totaling around EUR 1.5 million. The forecast for fiscal year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under EUR 230 million and net income of around EUR 25 million. The complete figures for the first quarter of 2023 will be published on May 11, 2023. Contact: End of Inside Information
25-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1616873 |
| End of Announcement | EQS News Service |
|
|
1616873 25-Apr-2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Eckert & Ziegler Strahlen- und Medizintechnik AG, ohne Sell-Einschätzungen.
Das Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 48.02 €.
